Search

Your search keyword '"Kimby, Eva"' showing total 798 results
Start Over Author "Kimby, Eva"
798 results on '"Kimby, Eva"'

101. First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

Author

Sylvan, Sandra Eketorp, primary, Asklid, Anna, additional, Johansson, Hemming, additional, Klintman, Jenny, additional, Bjellvi, Jenny, additional, Tolvgård, Staffan, additional, Kimby, Eva, additional, Norin, Stefan, additional, Andersson, Per-Ola, additional, Karlsson, Claes, additional, Karlsson, Karin, additional, Lauri, Birgitta, additional, Mattsson, Mattias, additional, Sandstedt, Anna Bergendahl, additional, Strandberg, Maria, additional, Österborg, Anders, additional, and Hansson, Lotta, additional

Published
2018
Full Text
View/download PDF

102. Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up

Author

Lockmer, Sandra, primary, Østenstad, Bjørn, additional, Hagberg, Hans, additional, Holte, Harald, additional, Johansson, Ann-Sofie, additional, Wahlin, Björn Engelbrekt, additional, Wader, Karin Fahl, additional, Steen, Chloé Beate, additional, Meyer, Peter, additional, Maisenhølder, Martin, additional, Smedby, Karin Ekström, additional, Brown, Peter, additional, and Kimby, Eva, additional

Published
2018
Full Text
View/download PDF

105. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).

Author

Moccia, Alden Alberto, Schär, Sämi, Hayoz, Stefanie, Pirosa, Maria Cristina, Taverna, Christian, Novak, Urban, Kimby, Eva, Ghielmini, Michele, and Zucca, Emanuele

Subjects
PROGNOSIS, CANCER research, LYMPHOMAS, RITUXIMAB
Abstract

Summary: The relapse of follicular lymphoma (FL) within 24 months (POD24) of chemoimmunotherapy has been associated with poor survival. We analyzed a pooled dataset of three randomized trials including FL patients with advanced disease, conducted by the Swiss Group for Clinical Cancer Research (SAKK). Overall, POD24 was observed in 27% of 318 patients, but rate variance among studies suggested that the rituximab schedule might affect POD24 rate. POD24 was associated with lower 10‐year overall survival rates than in the reference group (69% vs. 77%; hazard ratio, 3·12; 95% confidence interval, 1·73–5·65). POD24 retains its prognostic validity in patients treated without chemotherapy and may represent a useful end‐point for future studies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

107. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Author

Kolstad, Arne, Pedersen, Lone Bredo, Eskelund, Christian W., Husby, Simon, Gronbaek, Kirsten, Jerkeman, Mats, Laurell, Anna, Räty, Riikka, Elonen, Erkki, Andersen, Niels Smedegaard, Brown, Peter deNully, Kimby, Eva, Bentzen, Hans, Sundstrom, Christer, Ehinger, Mats, Karjalainen-Lindsberg, Marja-Liisa, Delabie, Jan, Ralfkiaer, Elisabeth, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Kuittinen, Outi, Niemann, Carsten, Geisler, Christian Hartman, Nordic Lymphoma Grp, Hematologian yksikkö, Clinicum, Department of Oncology, Department of Medicine, University of Helsinki, Medicum, Department of Pathology, and HUS Comprehensive Cancer Center

Subjects
Oncology, Male, Neoplasm, Residual, Lymphoma, Mantle-Cell, 0302 clinical medicine, Autologous stem-cell transplantation, Recurrence, hemic and lymphatic diseases, NETWORK, Hematopoietic Stem Cell Transplantation, TIME QUANTITATIVE PCR, Preemptive rituximab, Hematology, Middle Aged, Autologous stem cell, 3. Good health, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, Rituximab, Female, medicine.drug, PROGRESSION-FREE SURVIVAL, Adult, medicine.medical_specialty, 3122 Cancers, PHASE-2, Scandinavian and Nordic Countries, IMMUNOCHEMOTHERAPY, Transplantation, Autologous, 03 medical and health sciences, Median follow-up, Internal medicine, MULTIPLE-MYELOMA, medicine, Humans, PROGNOSTIC INDEX, Aged, Mantle cell lymphoma, business.industry, Minimal residual disease, REMISSION, medicine.disease, RANDOMIZED-TRIALS, Survival Analysis, Surgery, Lymphoma, body regions, 3121 General medicine, internal medicine and other clinical medicine, Immunoglobulin heavy chain, Bone marrow, business, 030215 immunology, transplantation, Follow-Up Studies
Abstract

The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P .0001). OS was 75% at 10 years and median not reached in the MRD-negative group, compared with only 35 months in the MRD-positive group (P .0001). Of the 86 patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after 10 years. For all patients, the median time from ASCT to first molecular relapse was 55 months, with a continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from first molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients in the first analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies.

Published
2016

108. M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy.

Author

Lockmer, Sandra, Ren, Weicheng, Brodtkorb, Marianne, Østenstad, Bjørn, Wahlin, Björn E., Pan‐Hammarström, Qiang, and Kimby, Eva

Subjects
RITUXIMAB, LYMPHOMAS, CLINICAL trials
Abstract

Summary: The clinical course of follicular lymphoma (FL) is highly variable. Recently the m7‐FL international prognostic index (FLIPI) integrating performance status, FLIPI score and the mutational status of seven genes, was shown to stratify patients into "low‐risk" and "high‐risk" with respect to 5‐year failure‐free survival after first‐line immunochemotherapy. Our aim was to evaluate the model after rituximab without chemotherapy. The Nordic Lymphoma Group performed two randomized clinical trials on indolent lymphoma patients receiving single rituximab and rituximab with interferon‐α2a. In total, 95 FL patients had sufficient fresh‐frozen diagnostic material for sequencing. A targeted panel for the genes EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP and CARD11 was utilized for m7‐FLIPI score calculation. With a median follow‐up of 10·6 years, 76% of patients were alive. No difference in time to treatment failure (TTF), defined as the interval between start of trial therapy and initiation of new therapy or death, nor overall survival (OS) was found between the m7‐FLIPI risk groups (log‐rank P = 0·94 and 0·99, respectively). EZH2 mutations were associated with longer TTF (log‐rank P = 0·04) and in EP300 mutations were associated with shorter TTF (log‐rank P = 0·01). We conclude that the prognostic value of the m7‐FLIPI clinicogenetic model seems dependent on therapeutic regimen. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

109. Prognostic Significance of Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

Author

Rosenwald, Andreas, Bens, Susanne, Advani, Ranjana, Barrans, Sharon, Copie-Bergman, Christiane, Elsensohn, Mad-Helenie, Natkunam, Yaso, Calaminici, Maria, Sander, Birgitta, Baia, Maryse, Smith, Alexandra, Painter, Daniel, Pham, Luu, Zhao, Shuchun, Ziepert, Marita, Jordanova, Ekaterina S., Molina, Thierry J., Kersten, Marie José, Kimby, Eva, and Klapper, Wolfram

Published
2019
Full Text
View/download PDF

111. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes

Author

Palma, Marzia, primary, Krstic, Aleksandra, additional, Peña Perez, Lucia, additional, Berglöf, Anna, additional, Meinke, Stephan, additional, Wang, Qing, additional, Blomberg, K. Emelie M., additional, Kamali-Moghaddam, Masood, additional, Shen, Qiujin, additional, Jaremko, Georg, additional, Lundin, Jeanette, additional, De Paepe, Ayla, additional, Höglund, Petter, additional, Kimby, Eva, additional, Österborg, Anders, additional, Månsson, Robert, additional, and Smith, C. I. Edvard, additional

Published
2018
Full Text
View/download PDF

116. Unmet needs in the scientific approach to older patients with lymphoma

Author

Bron, Dominique, primary, Aurer, Igor, additional, André, Marc P. E., additional, Bonnet, Christophe, additional, Caballero, Dolores, additional, Falandry, Claire, additional, Kimby, Eva, additional, Soubeyran, Pierre, additional, Zucca, Emanuele, additional, Bosly, Andre, additional, and Coiffier, Bertrand, additional

Published
2017
Full Text
View/download PDF

117. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium

Author

Stevens, Wendy B.C., primary, Mendeville, Matias, additional, Redd, Robert, additional, Clear, Andrew J., additional, Bladergroen, Reno, additional, Calaminici, Maria, additional, Rosenwald, Andreas, additional, Hoster, Eva, additional, Hiddemann, Wolfgang, additional, Gaulard, Philippe, additional, Xerri, Luc, additional, Salles, Gilles, additional, Klapper, Wolfram, additional, Pfreundschuh, Michael, additional, Jack, Andrew, additional, Gascoyne, Randy D., additional, Natkunam, Yasodha, additional, Advani, Ranjana, additional, Kimby, Eva, additional, Sander, Birgitta, additional, Sehn, Laurie H., additional, Hagenbeek, Anton, additional, Raemaekers, John, additional, Gribben, John, additional, Kersten, Marie José, additional, Ylstra, Bauke, additional, Weller, Edie, additional, and de Jong, Daphne, additional

Published
2017
Full Text
View/download PDF

118. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials

Author

Shi, Qian, primary, Flowers, Christopher R., additional, Hiddemann, Wolfgang, additional, Marcus, Robert, additional, Herold, Michael, additional, Hagenbeek, Anton, additional, Kimby, Eva, additional, Hochster, Howard, additional, Vitolo, Umberto, additional, Peterson, Bruce A., additional, Gyan, Emmanuel, additional, Ghielmini, Michele, additional, Nielsen, Tina, additional, De Bedout, Sabine, additional, Fu, Tommy, additional, Valente, Nancy, additional, Fowler, Nathan H., additional, Hoster, Eva, additional, Ladetto, Marco, additional, Morschhauser, Franck, additional, Zucca, Emanuele, additional, Salles, Gilles, additional, and Sargent, Daniel J., additional

Published
2017
Full Text
View/download PDF

119. Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Author

Vojdeman, Fie J., primary, Herman, Sarah E. M., additional, Kirkby, Nikolai, additional, Wiestner, Adrian, additional, van t’ Veer, Mars B., additional, Tjønnfjord, Geir E., additional, Itälä-Remes, Maija A., additional, Kimby, Eva, additional, Farooqui, Mohammed Z., additional, Polliack, Aaron, additional, Wu, Ka Lung, additional, Doorduijn, Jeanette K., additional, Alemayehu, Wendimagegn G., additional, Wittebol, Shulamiet, additional, Kozak, Tomas, additional, Walewski, Jan, additional, Abrahamse-Testroote, Martine C. J., additional, van Oers, Marinus H. J., additional, Geisler, Christian H., additional, and Niemann, Carsten U., additional

Published
2017
Full Text
View/download PDF

121. Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Author

Palma, Marzia, primary, Krstic, Aleksandra, additional, Berglöf, Anna, additional, Wang, Qing, additional, Blomberg, Emelie, additional, Meinke, Stephan, additional, Kamali-Moghaddam, Masood, additional, Shen, Qiujin, additional, Jaremko, Georg, additional, Lundin, Jeanette, additional, Kimby, Eva, additional, Höglund, Petter, additional, Månsson, Robert, additional, Österborg, Anders, additional, and Smith, Edvard, additional

Published
2016
Full Text
View/download PDF

122. Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Author

Kimby, Eva, primary, Rondeau, Stephanie, additional, Vanazzi, Anna, additional, Ostenstad, Bjorn, additional, Mey, Ulrich J.M., additional, Rauch, Daniel, additional, Wahlin, Björn E, additional, Hitz, Felicitas, additional, Hernberg, Micaela, additional, Johansson, Ann-Sofie, additional, de Nully Brown, Peter, additional, Hagberg, Hans, additional, Ferreri, Andres J.M., additional, Lohri, Andreas, additional, Novak, Urban, additional, Zander, Thilo, additional, Bersvendsen, Hanne, additional, Bergetzi, Mario, additional, Mingrone, Walter, additional, Krasniqi, Fatime, additional, Dirnhofer, Stefan, additional, Hawle, Hanne, additional, Berardi, Simona, additional, Ghielmini, Michele, additional, and Zucca, Emanuele, additional

Published
2016
Full Text
View/download PDF

124. Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Author

Flowers, Christopher, primary, Ou, Fang-Shu, additional, Shi, Qian, additional, Hoster, Eva, additional, Peterson, Bruce A., additional, Hochster, Howard S., additional, Brice, Pauline, additional, Ladetto, Marco, additional, Hiddemann, Wolfgang, additional, Marcus, Robert E, additional, Kimby, Eva, additional, Herold, Michael, additional, De Bedout, Sabine, additional, Nielsen, Tina, additional, Morschhauser, Franck, additional, Rummel, Mathias, additional, Hagenbeek, Anton, additional, Vitolo, Umberto, additional, Salles, Gilles A., additional, and Sargent, Daniel, additional

Published
2016
Full Text
View/download PDF

126. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone

Author

Cheson, Bruce D., primary, Trask, Peter C., additional, Gribben, John G., additional, Dimier, Natalie, additional, Kimby, Eva, additional, Lugtenburg, Pieternella J., additional, Thieblemont, Catherine, additional, Wassner-Fritsch, Elisabeth, additional, Launonen, Aino, additional, and Sehn, Laurie H., additional

Published
2016
Full Text
View/download PDF

127. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome

Author

Minnema, Monique C., primary, Kimby, Eva, additional, D’Sa, Shirley, additional, Fornecker, Luc-Matthieu, additional, Poulain, Stéphanie, additional, Snijders, Tom J., additional, Kastritis, Efstathios, additional, Kremer, Stéphane, additional, Fitsiori, Aikaterini, additional, Simon, Laurence, additional, Davi, Frédéric, additional, Lunn, Michael, additional, Castillo, Jorge J., additional, Patterson, Christopher J., additional, Le Garff-Tavernier, Magali, additional, Costopoulos, Myrto, additional, Leblond, Véronique, additional, Kersten, Marie-José, additional, Dimopoulos, Meletios A., additional, and Treon, Steven P., additional

Published
2016
Full Text
View/download PDF

128. Follicular Lymphoma - Focus on Therapy.

Author

KIMBY, Eva

Subjects
*LYMPHOMA diagnosis, *LYMPHOMA treatment, *CANCER chemotherapy, *CARBOXYLIC acids, *IMMUNOLOGICAL adjuvants, *LYMPHOMAS, *RADIOTHERAPY, *TUMOR classification, *RITUXIMAB, *SEVERITY of illness index, *CHLORAMBUCIL
Published
2019

129. The Proliferative History Index, Epicmit, Derived from Genome-Wide Epigenomic Profiling, Is a Key Driver of Clinical Survival in Splenic Marginal Zone Lymphoma

Author

Parker, Helen, Mirandari, Amatta, Jaramillo-Oquendo, Carolina, Duran-Ferrer, Marti, Stevens, Ben, Buermann, Lara, Amarasinghe, Harindra Eranthi, Thomas, Jaya, Carr, Louise J., Syeda, Shama, Sakthipakan, Methusha, Parry, Marina, Davies, Zadie, McIver-Brown, Neil, Xochelli, Aliki, Ennis, Sarah, Scarfo, Lydia, Ghia, Paolo, Kalpadakis, Christina H., Pangalis, Gerassimos, Rossi, Davide, Wagner, Simon, Ahearne, Matthew, Seifert, Marc, Plass, Christoph, Weichenhan, Dieter, Kimby, Eva, Sutton, Lesley Ann, Rosenquist, Richard, Forconi, Francesco, Stamatopoulos, Kostas, Salido, Marta, Ferrer, Ana, Thieblemont, Catherine, Oscier, David Graham, Walewska, Renata, Rose-Zerilli, Matthew JJ, Gibson, Jane, Martin Subero, Iñaki I., Oakes, Christopher C., Bryant, Dean J., and Strefford, Jonathan C.

Abstract

The epiCMIT (epigenetically-determined Cumulative MIToses) mitotic clock (Durran-Ferrer, 2020) tracks DNA hypo- and hyper-methylation changes in heterochromatin and H3K27me3-containing chromatin, respectively, providing a comprehensive record of B cell mitotic history (pre- and post-malignant transformation). Higher epiCMIT levels correlate with poor survival in CLL and MCL, suggesting that a greater mitotic history predicts future proliferative capacity. However, no studies have investigated epiCMIT in splenic marginal zone lymphoma (SMZL).

Published
2023
Full Text
View/download PDF

130. Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Author

Zucca, Emanuele, Schaer, Saemi, Vanazzi, Anna, Østenstad, Bjørn, Mey, Ulrich, Rauch, Daniel, Wahlin, Björn E., Hitz, Felicitas, Hernberg, Micaela, Johansson, Ann-Sofie, Brown, Peter de Nully, Hagberg, Hans, Ferreri, Andrés José María, Krasniqi, Fatime, Voegeli, Michèle, Novak, Urban, Zander, Thilo, Bersvendsen, Hanne, Mamot, Christoph, Mingrone, Walter, Stathis, Anastasios, Dirnhofer, Stefan, Hayoz, Stefanie, and Kimby, Eva

Abstract

Background:The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare the effectiveness of rituximab (R) alone versus R combined with lenalidomide (L) as the initial treatment for symptomatic follicular lymphoma (FL). The primary endpoint analysis, which demonstrated higher complete remission (CR) rates with the combination therapy, was previously reported (Zucca et al. Blood 2019). This report provides a long-term analysis of time-to-event endpoints with a median follow-up of approximately 10 years.

Published
2023
Full Text
View/download PDF

132. The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia

Author

Vojdeman, Fie Juhl, primary, van't Veer, Mars B., additional, Tjønnfjord, Geir E., additional, Itälä-Remes, Maija, additional, Kimby, Eva, additional, Polliack, Aaron, additional, Wu, Ka L., additional, Doorduijn, Jeanette K., additional, Alemayehu, Wendimagegn G., additional, Wittebol, Shulamiet, additional, Kozak, Tomas, additional, Walewski, Jan, additional, Abrahamse-Testroote, Martine C. J., additional, van Oers, Marinus H. J., additional, and Geisler, Christian Hartmann, additional

Published
2016
Full Text
View/download PDF

134. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

Author

Eskelund, Christian W., primary, Kolstad, Arne, additional, Jerkeman, Mats, additional, Räty, Riikka, additional, Laurell, Anna, additional, Eloranta, Sandra, additional, Smedby, Karin E., additional, Husby, Simon, additional, Pedersen, Lone B., additional, Andersen, Niels S., additional, Eriksson, Mikael, additional, Kimby, Eva, additional, Bentzen, Hans, additional, Kuittinen, Outi, additional, Lauritzsen, Grete F., additional, Nilsson-Ehle, Herman, additional, Ralfkiaer, Elisabeth, additional, Ehinger, Mats, additional, Sundström, Christer, additional, Delabie, Jan, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Workman, Christopher T., additional, Garde, Christian, additional, Elonen, Erkki, additional, Brown, Peter, additional, Grønbaek, Kirsten, additional, and Geisler, Christian H., additional

Published
2016
Full Text
View/download PDF

137. Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

Author

Cheson, Bruce D., primary, Trask, Peter C, additional, Gribben, John, additional, Dimier, Natalie, additional, Kimby, Eva, additional, Lugtenburg, Pieternella J, additional, Thieblemont, Catherine, additional, Wassner Fritsch, Elisabeth, additional, and Sehn, Laurie H, additional

Published
2015
Full Text
View/download PDF

140. Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Author

Eketorp Sylvan, Sandra, Asklid, Anna, Johansson, Hemming, Klintman, Jenny, Bjellvi, Jenny, Tolvgård, Staffan, Kimby, Eva, Norin, Stefan, Andersson, P-O, Karlsson, Claes, Karlsson, Karin, Lauri, Birgitta, Mattsson, Mattias, Sandstedt, Anna Bergendahl, Strandberg, Maria, Österborg, Anders, and Hansson, Lotta

Published
2017
Full Text
View/download PDF

142. Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

Author

Casulo, Carla, Le-Rademacher, Jennifer, Dixon, Jesse, Salles, Gilles, Hoster, Eva, Herold, Michael, Hiddemann, Wolfgang, Sebban, Catherine, Marcus, Robert, Kimby, Eva, Hochster, Howard, Vitolo, Umberto, Gyan, Emmanuel, Ou, Fang-Shu, Nielsen, Tina, Foon, Kenneth A., Qiuan, Shi, and Flowers, Christopher

Published
2017
Full Text
View/download PDF

143. Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant

Author

Pettengell, Ruth, Schmitz, N., Smith, Greame, Patton, William N, Metzner, Bernd, Caballero, Dolores, Tilly, Hervé, Walewski, Jan A., Bence-Bruckler, Isabelle, To, Bik, Geisler, Christian H., Schots, Henri, Kimby, Eva, Taverna, Christian J., Kozak, T., Uddin, Ruzena, Ruiz De Elvira, Carmen, Goldstone, Anthony H., and Hematology

Subjects
autologous stem cell transplantation, Follicular lymphoma
Abstract

Autologous transplantation significantly improves the progression free survival (PFS) and overall survival (OS) of patients with relapsed or resistant follicular (rFL) lymphoma compared with chemotherapy alone (Schouten H, et al. J Clin Oncol 2003;21:3918-27). Small phase II trials suggest, that rituximab (R) given peritransplant further improves survival outcome. Whilst the role of maintenance R post chemotherapy in FL is established, the benefit and safety of maintenance R following autologous transplant is unknown. In this randomised prospective study the efficacy and safety of R as in vivo purging pretransplant and as maintenance treatment immediately post transplant was assessed. From Oct 1999 to Apr 2006, 280 of a planned 420 R naïve patients with rFL in first (n=16), second (n= 222) or third remission (n=41) who achieved either a complete remission (n=83) or a very good partial remission (n=196) to induction chemotherapy, with limited bone marrow infiltration ( 0.5 x 109 /L was prompt, median 14.3 days(range 10-115) and platelets > 50 x 109/L,median 25.1 days (range 9-190). Time to engraftment and early or late toxicities did not differ significantly between the groups apart from a lower neutrophil count at 3 months in patients on maintenance. No graft failures or late neutropenia was reported. Transplant related mortality was 0.5%. Only 3 infection related deaths have been reported post 100 days. Two hundred and seventeen patients are alive on continued follow-up. Median follow-up is 6.4 years. PFS at 5 years was 62.9% for patients receiving RP + RM versus 37.6 % for patients receiving no R (logrank PFS; p=0.004; HR 0.76, 95%CI: 0.66 - 0.93). OS at 5 years was 79.5% % versus 78.4 % for patient receiving RP + RM versus no R (logrank PFS; p>0.1). Multivariate analysis was not able to define a high or low risk patient group. R in vivo purging and maintenance results in superior PFS compared to no R. R does not adversely affect peripheral blood stem cell harvesting or engraftment and maintenance R post transplant is safe. The impressive OS suggests that relapsed FL patients can be effectively salvaged post R purging and maintenance.

Published
2010

145. Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Author

Kimby, Eva, primary, Martinelli, Giovanni, additional, Ostenstad, Bjorn, additional, Mey, Ulrich JM, additional, Rauch, Daniel, additional, Wahlin, Björn E, additional, Hitz, Felicitas, additional, Hernberg, Micaela, additional, Johansson, Ann-Sofie, additional, Brown, Peter de Nully, additional, Hagberg, Hans, additional, Ferreri, Andrés J.M., additional, Lohri, Andreas, additional, Novak, Urban, additional, Zander, Thilo, additional, Bersvendsen, Hanne, additional, Bargetzi, Mario, additional, Mingrone, Walter, additional, Krasniqi, Fatime, additional, Dirnhofer, Stephan, additional, Hawle, Hanne, additional, Berardi, Simona, additional, Demmel, Steffi, additional, Rondeau, Stephanie, additional, and Zucca, Emanuele, additional

Published
2014
Full Text
View/download PDF

146. Follicular Lymphoma Survival in Sweden in the Rituximab Era

Author

Junlén, Henna Riikka, primary, Peterson, Stefan, additional, Kimby, Eva, additional, Lockmer, Sandra, additional, Linden, Ola, additional, Nilsson-Ehle, Herman, additional, Erlanson, Martin, additional, Hagberg, Hans, additional, Rådlund, Anders, additional, Hagberg, Oskar, additional, and Wahlin, Björn E, additional

Published
2014
Full Text
View/download PDF

147. T-Cell Levels Are Prognostic in Mantle Cell Lymphoma

Author

Nygren, Lina, primary, Wasik, Agata M., additional, Baumgartner-Wennerholm, Stefanie, additional, Jeppsson-Ahlberg, Åsa, additional, Klimkowska, Monika, additional, Andersson, Patrik, additional, Buhrkuhl, Daren, additional, Christensson, Birger, additional, Kimby, Eva, additional, Wahlin, Björn E., additional, and Sander, Birgitta, additional

Published
2014
Full Text
View/download PDF

149. Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma

Author

Bai, Baoyan, Wise, Jillian F., Vodák, Daniel, Nakken, Sigve, Sharma, Ankush, Blaker, Yngvild Nuvin, Brodtkorb, Marianne, Hilden, Vera, Trøen, Gunhild, Ren, Weicheng, Lorenz, Suzanne, Lawrence, Michael S., Myklebost, Ola, Kimby, Eva, Pan-Hammarstrom, Qiang, Meza-Zepeda, Leonardo, Beiske, Klaus, Smeland, Erlend B., Hovig, Eivind, Lingjærde, Ole Christian, Holte, Harald, and Myklebust, June Helen

Published
2022
Full Text
View/download PDF

150. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia

Author

Kimby, Eva Treon, Steven P. Anagnostopoulos, Athanasios and Dimopoulos, Meletios Garcia-Sanz, Ramon Gertz, Morie A. and Johnson, Stephen LeBlond, Veronique Fermand, Jean-Paul and Maloney, David G. Merlini, Giampaolo Morel, Pierre Morra, Enrica Nichols, Gwen Ocio, Enrique M. Owen, Roger Stone, Marvin Blade, Joan

Abstract

This report by an international consensus panel updates current recommendations for defining clinical response in Waldenstrom’s macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results